The future role of losartan

Area of Science:

• Pharmacological Therapy
• Cardiovascular Medicine
• Hypertension Management

Background:

• Arterial hypertension treatment has advanced significantly, with improved efficacy and tolerability of blood pressure-lowering drugs.
• Angiotensin II receptor antagonists, like losartan, represent a newer class of antihypertensive agents.
• Comparison with angiotensin converting enzyme (ACE) inhibitors highlights differences in mechanism and side-effect profiles.

Purpose of the Study:

• To compare the efficacy and tolerability of losartan with existing antihypertensive agents, specifically ACE inhibitors and atenolol.
• To evaluate losartan's effect on left ventricular hypertrophy (LVH) reversal.
• To explore the potential role of renin-angiotensin-aldosterone system (RAAS) interference in hypertension management and cardiovascular risk reduction.

Main Methods:

• Clinical studies comparing blood pressure reduction efficacy of losartan versus ACE inhibitors.
• Assessment of side-effect profiles, focusing on the incidence of cough.
• Evaluation of losartan's effectiveness in reversing left ventricular hypertrophy compared to atenolol.

Main Results:

• Losartan demonstrates comparable blood pressure-lowering efficacy to ACE inhibitors.
• Losartan exhibits a more favorable side-effect profile, with significantly less cough incidence than ACE inhibitors, likely due to unaffected bradykinin metabolism.
• Losartan is more effective than atenolol in reversing left ventricular hypertrophy.

Conclusions:

• Interference with the RAAS appears beneficial for reversing cardiovascular hypertrophic changes.
• Losartan's combination of efficacy, tolerability, and potential prognostic benefits suggests a significant future role in hypertension treatment.
• Further research into RAAS interference and ACE gene polymorphism may strengthen its therapeutic importance.